Literature DB >> 16406993

Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival.

Matthew K Tollefson1, Bradley C Leibovich, Jeffrey M Slezak, Horst Zincke, Michael L Blute.   

Abstract

PURPOSE: We determined the long-term clinical significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer.
MATERIALS AND METHODS: We reviewed the records of all patients who underwent bilateral pelvic lymph node dissection and radical retropubic prostatectomy for Gleason score 7 prostate cancer at our institution. All patients who underwent adjuvant hormonal or radiation therapy were excluded from analysis. Patients were monitored for biochemical failure, that is PSA progression, systemic recurrence and cancer specific survival.
RESULTS: We identified 1,688 patients who met admission criteria, of whom 1,256 (74.4%) had primary Gleason pattern 3 and 432 (25.6%) had primary Gleason pattern 4. Median followup was 6.9 years. At 10 years primary Gleason pattern 3 was associated with increased biochemical recurrence-free survival (48% vs 38%, p <0.001), lower systemic recurrence (8% vs 15%, p <0.001) and higher cancer specific survival (97% vs 93%, p = 0.013) for Gleason primary grades 3 and 4, respectively. All of these end points remained significant on multivariate analysis when controlling for preoperative PSA, seminal vesicle involvement, margin status, DNA ploidy and TNM staging. PSA doubling time was shorter in patients with primary Gleason pattern 4 (1.64 vs 1.01 years). Systemic recurrence and cancer specific survival were associated with a PSA doubling time of less than 1 year.
CONCLUSIONS: Gleason score 7 prostate cancer is a heterogeneous entity. We should continue to stratify patients according to primary Gleason pattern. Patients with Gleason score 4 + 3 prostate cancer have more aggressive disease and experience higher rates of biochemical failure, systemic recurrence and cancer specific death.

Entities:  

Mesh:

Year:  2006        PMID: 16406993     DOI: 10.1016/S0022-5347(05)00152-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

Review 1.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

2.  Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study.

Authors:  R Mathieu; M Moschini; B Beyer; K M Gust; T Seisen; A Briganti; P Karakiewicz; C Seitz; L Salomon; A de la Taille; M Rouprêt; M Graefen; S F Shariat
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-01-10       Impact factor: 5.554

3.  Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology.

Authors:  Daniel I Glazer; Elmira Hassanzadeh; Andriy Fedorov; Olutayo I Olubiyi; Shayna S Goldberger; Tobias Penzkofer; Trevor A Flood; Paul Masry; Robert V Mulkern; Michelle S Hirsch; Clare M Tempany; Fiona M Fennessy
Journal:  Abdom Radiol (NY)       Date:  2017-03

4.  Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era.

Authors:  Ahva Shahabi; Raj Satkunasivam; Inderbir S Gill; Gary Lieskovsky; Sia Daneshmand; Jacek K Pinski; Mariana C Stern
Journal:  Can Urol Assoc J       Date:  2016-01-14       Impact factor: 1.862

5.  Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratification method.

Authors:  Nicholas G Zaorsky; Tianyu Li; Karthik Devarajan; Eric M Horwitz; Mark K Buyyounouski
Journal:  Cancer       Date:  2012-04-27       Impact factor: 6.860

6.  In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT.

Authors:  Youngho Seo; Carina Mari Aparici; Matthew R Cooperberg; Badrinath R Konety; Randall A Hawkins
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

7.  Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study.

Authors:  Flavie Bratan; Emilie Niaf; Christelle Melodelima; Anne Laure Chesnais; Rémi Souchon; Florence Mège-Lechevallier; Marc Colombel; Olivier Rouvière
Journal:  Eur Radiol       Date:  2013-03-15       Impact factor: 5.315

8.  Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database.

Authors:  David E Kang; Nicholas J Fitzsimons; Joseph C Presti; Christopher J Kane; Martha K Terris; William J Aronson; Christopher L Amling; Stephen J Freedland
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

Review 9.  Pathologic basis of focal therapy for early-stage prostate cancer.

Authors:  Vladimir Mouraviev; Janice M Mayes; Thomas J Polascik
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

10.  The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional Cancer Hospital Database.

Authors:  Ryan S Turley; Martha K Terris; Christopher J Kane; William J Aronson; Joseph C Presti; Christopher L Amling; Stephen J Freedland
Journal:  BJU Int       Date:  2008-09-03       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.